Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
The Core Decision (Made Before Hour 1) The side effect is real, serious, and known to me now. Patients are currently taking this drug without informed consent about a ~1-in-8,000 liver failure risk. Everything else — stock price, board pressure, legal exposure — is secondary.Read the full answer
As CEO, my primary fiduciary and ethical duty is to patients, regulators, and long-term shareholder value. The "6-month reporting timeline" cited by legal is almost certainly a misunderstanding of regulatory processes (likely conflating initial adverse event reporting with full label amendment review).Read the full answer